184 related articles for article (PubMed ID: 37410084)
21. Potential impact of combined high- and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2.
Okadome M; Saito T; Tanaka H; Nogawa T; Furuta R; Watanabe K; Kita T; Yamamoto K; Mikami M; Takizawa K;
J Obstet Gynaecol Res; 2014 Feb; 40(2):561-9. PubMed ID: 24147758
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.
Saeki Y; Saito M; Irie T; Itoh F; Enatsu A; Komura H; Fujii M; Fujii R; Hidaka N; Maehama T; Shirasu N; Waseda T; Shibata T; Takada E; Mibe K; Sakamoto J; Yamada S; Takakura M; Sasagawa T
J Med Virol; 2024 Feb; 96(2):e29413. PubMed ID: 38314927
[TBL] [Abstract][Full Text] [Related]
23. Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
Malagón T; Volesky KD; Bouten S; Laprise C; El-Zein M; Franco EL
Int J Cancer; 2020 Nov; 147(10):2695-2707. PubMed ID: 32363604
[TBL] [Abstract][Full Text] [Related]
24. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
Silver MI; Schiffman M; Fetterman B; Poitras NE; Gage JC; Wentzensen N; Lorey T; Kinney WK; Castle PE
Cancer; 2016 Dec; 122(23):3682-3686. PubMed ID: 27657992
[TBL] [Abstract][Full Text] [Related]
25. The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
Stoler MH; Wright TC; Parvu V; Vaughan L; Yanson K; Eckert K; Karchmer T; Kodsi S; Cooper CK
Gynecol Oncol; 2018 Jun; 149(3):498-505. PubMed ID: 29681462
[TBL] [Abstract][Full Text] [Related]
26. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women.
Massad LS; Xie X; Burk RD; D'Souza G; Darragh TM; Minkoff H; Colie C; Burian P; Palefsky J; Atrio J; Strickler HD
Am J Obstet Gynecol; 2016 Mar; 214(3):354.e1-6. PubMed ID: 26433170
[TBL] [Abstract][Full Text] [Related]
27. Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women.
Clarke MA; Gradissimo A; Schiffman M; Lam J; Sollecito CC; Fetterman B; Lorey T; Poitras N; Raine-Bennett TR; Castle PE; Wentzensen N; Burk RD
Clin Cancer Res; 2018 May; 24(9):2194-2202. PubMed ID: 29420222
[No Abstract] [Full Text] [Related]
28. Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program.
Rosário A; Sousa A; Marinho-Dias J; Medeiros R; Lobo C; Leça L; Coimbra N; Tavares F; Baldaque I; Martins G; Monteiro P; Henrique R; Sousa H
J Med Virol; 2023 Jan; 95(1):e28414. PubMed ID: 36541747
[TBL] [Abstract][Full Text] [Related]
29. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
30. No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study.
Wentzensen N; Nason M; Schiffman M; Dodd L; Hunt WC; Wheeler CM;
J Infect Dis; 2014 Mar; 209(6):855-64. PubMed ID: 24179110
[TBL] [Abstract][Full Text] [Related]
31. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results.
Harris TG; Burk RD; Palefsky JM; Massad LS; Bang JY; Anastos K; Minkoff H; Hall CB; Bacon MC; Levine AM; Watts DH; Silverberg MJ; Xue X; Melnick SL; Strickler HD
JAMA; 2005 Mar; 293(12):1471-6. PubMed ID: 15784870
[TBL] [Abstract][Full Text] [Related]
32. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
33. Polymorphisms in the Nonhomologous End-joining DNA Repair Pathway are Associated with HPV Integration in Cervical Dysplasia.
Geris JM; Amirian ES; Marquez-Do DA; Guillaud M; Dillon LM; Follen M; Scheurer ME
Cancer Prev Res (Phila); 2023 Aug; 16(8):461-469. PubMed ID: 37217238
[TBL] [Abstract][Full Text] [Related]
34. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
[No Abstract] [Full Text] [Related]
35. Tumor necrosis factor (TNF) alpha and interleukin (IL) 18 genes polymorphisms are correlated with susceptibility to HPV infection in patients with and without cervical intraepithelial lesion.
Tavares MC; de Lima Júnior SF; Coelho AV; Marques TR; de Araújo DH; Heráclio Sde A; Amorim MM; de Souza PR; Crovella S
Ann Hum Biol; 2016 May; 43(3):261-8. PubMed ID: 26079218
[TBL] [Abstract][Full Text] [Related]
36. Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands.
Schurink-van 't Klooster TM; Siebers AG; Hoes J; van Kemenade FJ; Berkhof J; Bogaards JA; de Melker HE
Cancer Med; 2023 May; 12(10):11786-11794. PubMed ID: 36965085
[TBL] [Abstract][Full Text] [Related]
37. Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study.
Wentzensen N; Wilson LE; Wheeler CM; Carreon JD; Gravitt PE; Schiffman M; Castle PE
Cancer Res; 2010 Nov; 70(21):8578-86. PubMed ID: 20959485
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer.
Wheeler CM; Hunt WC; Schiffman M; Castle PE;
J Infect Dis; 2006 Nov; 194(9):1291-9. PubMed ID: 17041856
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.
Wang SS; Zuna RE; Wentzensen N; Dunn ST; Sherman ME; Gold MA; Schiffman M; Wacholder S; Allen RA; Block I; Downing K; Jeronimo J; Carreon JD; Safaeian M; Brown D; Walker JL
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):113-20. PubMed ID: 19124488
[TBL] [Abstract][Full Text] [Related]
40. Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women.
Hosaka M; Fujita H; Hanley SJ; Sasaki T; Shirakawa Y; Abiko M; Kudo M; Kaneuchi M; Watari H; Kikuchi K; Sakuragi N
Int J Cancer; 2013 Jan; 132(2):327-34. PubMed ID: 22729477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
